Abstract:Background. The application of potent immunosuppressants has decreased the incidence of acute rejection and increased short- and long-term graft survival; however, these drugs cause a variety of complications. In China, many transplant centers have adopted the immunosuppressive protocols based on the white population, neglecting the differences between the races. The purpose of this study was to explore a suitable immunosuppressive regimen for Chinese renal allograft recipients.Methods. Two hundred cadaveric renal allograft recipients who underwent transplantation between July 1999 and October 2001 were observed. Before October 2000, 104 recipients received the conventional dose of immunosuppressants; thereafter, 96 recipients received lower dose treatment. Doses of immunosuppressive agents, the incidence of acute rejection and pulmonary infection, and patient and graft survival rates were compared between the two groups.Results. Doses of mycophenolate mofetil (MMF) and cyclosporine A (CsA) administered in the conventional dose group were significantly higher than in the lower dose group at 3 months posttransplant, as was prednisone at 6 months posttransplant. The incidence of acute rejection and subclinical rejection that was biopsy-proven or diagnosed by clinical manifestations was 17.3% and 19.8%, respectively, in the conventional dose group and the lower dose group within the first 6 months, and no significant difference was noted (P=0.55). The incidence of pulmonary infection, especially severe infection, was much higher in the conventional treatment group (40.1% and 26.9%, respectively) than that in the lower dose group (11.5% and 5.2%, respectively), and the differences were statistically significant (P<0.001). The corresponding 1-year survival rate of patients was 87.4% and 97.9% (P<0.01), and that of renal grafts was 85.5% and 96.9% (P<0.01), for patients receiving conventional dose and lower dose immunosuppressive drugs, respectively. The rate of death with a functioning allograft caused by infection in the conventional dose group was significantly higher than that in the lower dose group (12.5% vs. 0%, P<0.01).Conclusions. The regimen of lower dose MMF, CsA, and prednisone in combination can significantly reduce the incidence of pulmonary infection, especially severe pulmonary infection, without increasing the incidence and severity of allograft rejection.

Concentrations of cyclosporine‐A and its metabolites in transplanted human kidney tissue during rejection and stable graft function

Relationship between cyclophilin A Mrna expression and acute rejection of human graft kidney

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

C4d as a significant predictor for humoral rejection in renal allografts.

Relatively depressed serum β2 microglobulin levels in cyclosporine‐treated renal transplant patients with graft rejection

Urinary C-X-C Motif Chemokines 13 is a Noninvasive Biomarker of Antibody-Mediated Renal Allograft Rejection

Assessment of Cyclosporine A Withdrawal in Renal Allograft Transplant Recipients

Monitoring of Ex Vivo Cyclosporin a Activity in Healthy Volunteers Using T Cell Function Assays in Relation to Whole Blood and Cellular Pharmacokinetics

Effects of CD20+ B-cell Infiltration into Allografts on Kidney Transplantation Outcomes: a Systematic Review and Meta-Analysis

Monitoring of Nuclear Factor of Activated T-cell-regulated Gene Expression in De Novo and Long-Term Liver Transplant Recipients Treated with Cyclosporine A.

The importance of early cyclosporine levels in pediatric kidney transplantation

Improved Clinical Outcomes in Chinese Renal Allograft Recipients Receiving Lower Dose Immunosuppressants

Association Between the Intracellular Tacrolimus Concentration in CD3 + T Lymphocytes and CD14 + Monocytes and Acute Kidney Transplant Rejection

Evaluation of Factors Related to Blood Concentration of Cyclosporine A in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Conversion from Cyclosporine to Tacrolimus in Patients with Chronic Allograft Nephropathy

Efficacy and side‐effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients *

The effect of cyclosporine on prognostic factors in cadaveric renal retransplantation

Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?

Equivalence of cyclosporine blood level assays in patients receiving cyclosporine microemulsion or cyclosporine

Monitoring Intra-cellular Tacrolimus Concentrations in Solid Organ Transplantation: Use of Peripheral Blood Mononuclear Cells and Graft Biopsy Tissue